Amgen’s Next-Generation Heart Drug Enters Phase III with Positive Results

Washington Drug Letter
A A
Amgen’s first long-term trial for its next-generation heart drug evolocumab has shown positive results, heating up the race to develop the emerging class of drugs known as PCSK9 inhibitors.

To View This Article:

Login